{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:58:34Z","timestamp":1785571114287,"version":"3.56.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiac disease has become the primary cause of death among individuals with Duchenne Muscular Dystrophy. There are currently no published data on the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with dystrophin deficient cardiomyopathy. The purpose of this study was to analyze the use of SGLT2i in patients with dystrophin deficient cardiomyopathy and describe indications for therapy, effects on cardiac function, and adverse effects. We utilized the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) dystrophinopathy registry to review patients on SGLT2i. 80 patients were initiated on an SGLT2i. The median age at initiation was 19.6 years and median weight was 66.8\u00a0kg. Most patients were already prescribed three other cardiac medications classes. At initiation, the median ejection fraction (EF) was 37% (IQR 30.0-42.3%) by echocardiogram and 37% (IQR 31.5\u201341.0%) by cardiac magnetic resonance imaging (cMRI). Follow-up data was collected for 55 patients with a median follow-up time of 1.4 years. At follow-up, the median EF was 40% (IQR 32-47.8%) by echocardiogram and 39% (IQR 33-40.2%) by cMRI. There were 14 adverse events which included bone fracture (5%), acute kidney injury (5%), urinary tract infection (2.5%), genitourinary infection (1.3%) and others (3.8%). Seven patients (8.8%) required permanent discontinuation. This medication appears well tolerated with a low incidence of adverse effects. Longer term follow-up data is needed. However, SGLT2i may represent an additional therapy for slowing the progression of cardiac disease.<\/jats:p>","DOI":"10.1007\/s00246-026-04410-0","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:45:09Z","timestamp":1785570309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of SGLT2 Inhibitors in Dystrophin Deficient Cardiomyopathy: A Multi-center Study Using the ACTION Registry"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4287-3658","authenticated-orcid":false,"given":"Rachel E.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Wittlieb-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Esteso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Shugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin K.","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Mokshagundam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Radel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Profita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aislinn","family":"DeSieghardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kroslowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"22","key":"4410_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1136\/heartjnl-2017-311269","volume":"103","author":"D D\u2019Amario","year":"2017","unstructured":"D\u2019Amario D, Amodeo A, Adorisio R et al (2017) A current approach to heart failure in Duchenne muscular dystrophy. Heart 103(22):1770\u20131779","journal-title":"Heart"},{"issue":"2","key":"4410_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","volume":"14","author":"SV Raman","year":"2015","unstructured":"Raman SV, Hor KN, Mazur W et al (2015) Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14(2):153\u2013161","journal-title":"Lancet Neurol"},{"issue":"1","key":"4410_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12872-017-0627-x","volume":"17","author":"S Mavrogeni","year":"2017","unstructured":"Mavrogeni S, Giannakopoulou A, Papavasiliou A et al (2017) Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with\/without perindopril. BMC Cardiovasc Disord 17(1):197","journal-title":"BMC Cardiovasc Disord"},{"issue":"16","key":"4410_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"11","key":"4410_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J et al (2021) Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J Am Coll Cardiol 77(11):1381\u20131392","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"4410_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 79(17):1757\u20131780","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4410_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","volume":"44","author":"DM Newland","year":"2023","unstructured":"Newland DM, Law YM, Albers EL et al (2023) Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol 44(1):146\u2013152","journal-title":"Pediatr Cardiol"},{"key":"4410_CR8","doi-asserted-by":"crossref","unstructured":"Dunne EC, Tricca L, Bachiri N et al (2026) The use of dapagliflozin in infants and children with heart failure. Pediatr Cardiol","DOI":"10.1007\/s00246-026-04259-3"},{"issue":"10","key":"4410_CR9","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.healun.2025.06.003","volume":"44","author":"C Irving","year":"2025","unstructured":"Irving C, Azeka E, Adorisio R et al (2025) The international society for heart and lung transplantation guidelines for the management of pediatric heart failure (Update From 2014). J Heart Lung Transpl 44(10):e21\u2013e71","journal-title":"J Heart Lung Transpl"},{"key":"4410_CR10","doi-asserted-by":"crossref","unstructured":"Butts R, Nandi D, Hong B et al (2025) Use of SGLT2 inhibitors in pediatric heart failure: a multi-center study. Pediatr Cardiol","DOI":"10.1007\/s00246-025-04025-x"},{"issue":"4","key":"4410_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1017\/S1047951125000587","volume":"35","author":"P Esteso","year":"2025","unstructured":"Esteso P, Auerbach SR, Bansal N et al (2025) Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee. Cardiol Young 35(4):770\u2013775","journal-title":"Cardiol Young"},{"key":"4410_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","volume":"167","author":"JRB Dyck","year":"2022","unstructured":"Dyck JRB, Sossalla S, Hamdani N et al (2022) Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol 167:17\u201331","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"4410_CR13","doi-asserted-by":"publisher","first-page":"e010040","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040","volume":"16","author":"JH Soslow","year":"2023","unstructured":"Soslow JH, Xu M, Slaughter JC et al (2023) Cardiovascular measures of all-cause mortality in duchenne muscular dystrophy. Circ Heart Fail 16(8):e010040","journal-title":"Circ Heart Fail"},{"issue":"12","key":"4410_CR14","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","volume":"34","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang F, Zhang Y et al (2023) Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporos Int 34(12):2013\u20132025","journal-title":"Osteoporos Int"},{"key":"4410_CR15","doi-asserted-by":"crossref","unstructured":"Lambrou GI, Samartzi A, Vlachou E et al (2025) Is the Impact of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review. Med (Basel). 12(2)","DOI":"10.3390\/medicines12020010"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04410-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-026-04410-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04410-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:45:10Z","timestamp":1785570310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-026-04410-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":15,"alternative-id":["4410"],"URL":"https:\/\/doi.org\/10.1007\/s00246-026-04410-0","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"18 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}